规格: | 98% |
分子量: | 691.61 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
Background:
PD-1/PD-L1-IN 7 is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. PD-1/PD-L1-IN 7 has anticancer and antiviral functions[1].
PD-1/PD-L1-IN 7 (compound 139) enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. PD-1/PD-L1-IN 7 also enhances the frequency of GrB+ cells among HBV-specific CD8+ and CD4+ T cells. The ability of PD-1/PD-L1-IN 7 to enhance the antiviral functions of HBV-specific CD8+ and CD4+ T cells in vitro is comparable to those of Durvalumab[1].
PD-1/PD-L1-IN 7 (Compound 139; 10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment shows >90% PD-L1 target occupancy (TO) on the tumor cells. PD-1/PD-L1-IN 7 significantly inhibits tumor growth in a human PD-L1 expressing MC38 mouse colorectal tumor model[1].
[1]. Evangelos Aktoudianakis, et al. Pd-1/pd-l1 inhibitors. WO2019160882A1.